Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quality of life study of topical imiquimod for actinic keratosis and superficial basal cell carcinoma
NL-OMON33695Recruiting
- Sponsor
- Erasmus MC
- Start
- Jun 2009
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of imiquimod in actinic keratosis (AK) and basal cell carcinoma (BCC), sponsored by Erasmus MC. Primary endpoints: Change in health-related quality of life, Treatment satisfaction and 3 more. Started Jun 2009; status: recruiting.
02
Drugs
imiquimod
03
Conditions
actinic keratosis (AK)basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NL-OMON33695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33695.